Abstracts

TB Outcomes With ATV/r and Two Rifamycin-Containing TB Regimens in HIV/TB in India

Tuberculosis (TB) is the leading cause of death globally in HIV-infected individuals, and drug interactions can complicate treatment in this population.  For those requiring antiretroviral therapy (ART) that includes a boosted protease inhibitor (PI), rifabutin is the recommended rifamycin, although the optimal dose is still in question.  Our hypothesis was that HIV/TB co-infected patients treated…

Treatment Outcomes for HIV/MDR-TB Coinfection in the Era of Antiretroviral Therapy

The convergence of HIV and multidrug-resistant tuberculosis (MDR-TB) epidemics is a major global health threat. HIV co-infection has been shown to increase the risk of poor treatment outcomes among MDR-TB patients, but few studies have examined whether concomitant administration of antiretroviral therapy (ART) at a programmatic-level could achieve high rates of treatment success among HIV-infected…

Initiating cART in Pregnancy: Impact on HIV RNA Decay

cART reduces HIV mother-to-child transmission, allowing vaginal delivery if viral load is low. cART is evolving and the optimal regimen for initiating treatment in pregnancy uncertain. Routine clinical care data from nine London and Brighton sites, 2001 to 2015, were anonymised and collated. Demographics, baseline and subsequent HIV plasma loads, delivery information and ART were…

Viraemic Episodes Occur Frequently in Postpartum South African Women on ART

With growing numbers of pregnant women starting antiretroviral (ART) there are significant concerns regarding adherence, especially during the postpartum (PP) period. Viral load (VL) monitoring for pregnant and PP women is promoted in international guidelines to identify nonadherence and treatment failure, but little is known about the frequency and magnitude of elevated VL in this…

Viral Suppression and Retention 2-5 Years After ART Initiation in Pregnancy in Uganda

Recent studies have demonstrated that up to 40% of women are lost to follow-up after initiating antiretroviral therapy (ART) during pregnancy in Option B+ programs. Data are limited on long-term virologic outcomes and retention in care, particularly after cessation of breastfeeding. We evaluated retention in care and viral suppression (VS) 2-5 years postpartum among previously…